Ombitasvir, also known as ABT-267, is a NS5A inhibitor, and is an antiviral drug for the treatment of hepatitis C virus (HCV) infection. In the United States, it is approved by the Food and Drug Administration for use in combination with paritaprevir, ritonavir and dasabuvir in the product Viekira Pak. Ombitasvir acts by inhibiting the HCV protein NS5A.
HCV Protease Inhibitors Related Prodcuts:
Daclatasvir; Daclatasvir hcl; Telaprevir; Lomibuvir; Danoprevir; Paritaprevir; Paritaprevir dihydrate; Grazoprevir; Elbasvir; Simeprevir; Velpatasvir; Ledipasvir; Boceprevir